Molecular biomarkers play a key role in prognosis and treatment decisions for a variety of tumours; for example, PD-1 and PD-L1 are not only prognostic markers for a variety of tumours, but also key indicators for immune checkpoint therapy [12]. Here, CD274 is linked to neoplasm.